Zentalis Pharmaceuticals Ownership
| ZNTL Stock | USD 1.76 0.11 5.88% |
Shares in Circulation | First Issued 2019-03-31 | Previous Quarter 71 M | Current Value 71.1 M | Avarage Shares Outstanding 47.5 M | Quarterly Volatility 17.4 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Zentalis |
Zentalis Stock Ownership Analysis
About 16.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.4. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zentalis Pharmaceuticals recorded a loss per share of 2.5. The entity had not issued any dividends in recent years. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. The company was incorporated in 2014 and is based in New York, New York. Zentalis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people. For more information please call Kimberly MD at 212 433 3791 or visit https://zentalis.com.Besides selling stocks to institutional investors, Zentalis Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Zentalis Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Zentalis Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Zentalis Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
About 16.0% of Zentalis Pharmaceuticals Llc are currently held by insiders. Unlike Zentalis Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Zentalis Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Zentalis Pharmaceuticals' insider trades
Zentalis Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Zentalis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zentalis Pharmaceuticals Llc backward and forwards among themselves. Zentalis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Zentalis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 1.3 M | D. E. Shaw & Co Lp | 2024-12-31 | 1.2 M | Verition Fund Managegment, Llc | 2024-12-31 | 1.2 M | Mpm Oncology Impact Management Lp | 2024-12-31 | 1.1 M | Integral Health Asset Management, Llc | 2024-12-31 | 1.1 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 979.9 K | Tybourne Capital Management (hk) Ltd | 2024-12-31 | 961.5 K | Millennium Management Llc | 2024-12-31 | 957.6 K | Pfizer Inc | 2024-12-31 | 953.8 K | Matrix Capital Management Company, Llc | 2024-12-31 | 14 M | Eventide Asset Management, Llc | 2024-12-31 | 4.5 M |
Zentalis Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zentalis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zentalis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zentalis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zentalis Pharmaceuticals Outstanding Bonds
Zentalis Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Zentalis Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Zentalis bonds can be classified according to their maturity, which is the date when Zentalis Pharmaceuticals Llc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zentalis Pharmaceuticals Llc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zentalis Pharmaceuticals. If investors know Zentalis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zentalis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Zentalis Pharmaceuticals is measured differently than its book value, which is the value of Zentalis that is recorded on the company's balance sheet. Investors also form their own opinion of Zentalis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zentalis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zentalis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zentalis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zentalis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zentalis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zentalis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.